424B3PROSPECTUS
Jul 7, 2026Final prospectus0001683168-26-005322
All companies
Trade Aethlon Medical Inc
AE
Aethlon Medical Inc
AEMDPublicArchived
Public / ArchivedUnited States(NASDAQ-CM)Best valuation $1.78M1 market
Public listing
Listed· NASDAQ-CM· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-harvest, sec-edgar, nasdaq
IPO Calendar · NASDAQ-CMIPO
AEMDPrice
$2.51
24h
+3.29%
Valuation
$1.78M
24h volume
$290.66K
Type
IPO
Trade Aethlon Medical IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Financials
UnprofitableFrom SEC filings, latest FY ending Mar 31, 2024 · CIK 0000882291.
Revenue · -100.00% YoY
$0
Net income
-$7.15M
Gross margin
—
Cash
$5.03M
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $574.25K | $294.17K |
| Operating income | -$7.29M | -$9.34M | -$12.64M | -$11.9M | -$10.42M |
| Net income | -$7.15M | -$13.4M | -$12.21M | -$12.03M | -$10.42M |
| R&D expense | $1.91M | $2.21M | $2.52M | $2.75M | $2.34M |
| Cash & equivalents | $5.03M | $5.5M | $5.44M | $14.53M | $17.07M |
| Total assets | $6.33M | $7.36M | $8.25M | $17.51M | $19.42M |
| Total liabilities | $1.45M | $2.24M | $2.48M | $2.44M | $2.43M |
| Shareholders' equity | $4.89M | $5.12M | $5.77M | $15.06M | $16.99M |
About Aethlon Medical Inc
Aethlon Medical is a medical-technology company developing the Hemopurifier, a clinical-stage blood-filtration device for cancer, viral infections, and transplant-related applications.
What the company does
- Develops extracorporeal blood-purification technology intended to remove harmful exosomes, exosomal particles, and life-threatening viruses from biological fluids.
- Advances the Hemopurifier through clinical studies and regulatory work, including FDA breakthrough-device designations for oncology and viral-infection indications.
- Explores use cases in advanced cancer, infectious disease, and organ-transplant settings where existing therapies may be limited.
Business profile
Aethlon Medical operates in clinical-stage medtech, where clinical evidence, regulatory clearance, manufacturing readiness, and specialist adoption determine commercial potential.
SEC IPO filings
Final prospectusEDGAR filings resolved from AEMD / CIK 0000882291.
Jul 6, 2026Effective9999999995-26-002203
S-1/AAMENDMENT NO 2
Jul 1, 2026Amended0001683168-26-005219
S-1/AAMENDMENT NO. 1
Jul 1, 2026Amended0001683168-26-005203
Jun 22, 2026Filed0001683168-26-005003
May 5, 2026Confidential draft0001683168-26-003479
424B3FORM 434(B)(3)
Jan 27, 2026Final prospectus0001683168-26-000566
Jan 16, 2026Effective9999999995-26-000202
424B3PROSPECTUS
Jan 16, 2026Final prospectus0001683168-26-000376
CORRESPfilename1.htm
Jan 14, 2026SEC correspondence0001683168-26-000306
UPLOADfilename1.pdf
Jan 13, 2026SEC correspondence0000000000-26-000439
Jan 7, 2026Filed0001683168-26-000137
Aethlon Medical Inc IPO — frequently asked questions
- When did Aethlon Medical Inc go public?
- Aethlon Medical Inc has already gone public and now trades publicly on NASDAQ-CM under the ticker AEMD.
- Can I buy Aethlon Medical Inc stock?
- Yes — Aethlon Medical Inc is publicly traded on NASDAQ-CM as AEMD. You can follow its live price, valuation and post-IPO performance above.
- What is Aethlon Medical Inc's valuation?
- Aethlon Medical Inc's most recent valuation tracked here is $1.78M, derived from live market prices.